Cargando…

Targeting the mTOR pathway using novel ATP-competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma

Mechanistic target of rapamycin (mTOR), which functions via two multiprotein complexes termed mTORC1 and mTORC2, is positioned in the canonical phosphoinositide 3-kinase-related kinase (PI3K)/AKT (PI3K/AKT) pathways. These complexes exert their actions by regulating other important kinases, such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amin, Anubhav G., Jeong, Seung Won, Gillick, John L., Sursal, Tolga, Murali, Raj, Gandhi, Chirag D., Jhanwar-Uniyal, Meena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448541/ https://www.ncbi.nlm.nih.gov/pubmed/34523696 http://dx.doi.org/10.3892/ijo.2021.5263

Ejemplares similares

Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
por: Park, Seohyun, et al.
Publicado: (2016)

Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
por: Francipane, Maria Giovanna, et al.
Publicado: (2013)

Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors †
por: Shaik, Althaf, et al.
Publicado: (2018)

Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells
por: Waetzig, Rebecca, et al.
Publicado: (2021)

Involvement of mTOR Pathways in Recovery from Spinal Cord Injury by Modulation of Autophagy and Immune Response
por: Vargova, Ingrid, et al.
Publicado: (2021)

Torin 1 partially corrects vigabatrin-induced mitochondrial increase in mouse
por: Vogel, Kara R, et al.
Publicado: (2015)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

Transcriptomic Analysis of the Effect of Torin-2 on the Central Nervous System of Drosophila melanogaster
por: Vershinina, Yulia S., et al.
Publicado: (2023)

Torin2 inhibits the EGFR-TKI resistant Non-Small Lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling
por: Hu, Yi, et al.
Publicado: (2020)

The protective role of autophagy in experimental osteoarthritis, and the therapeutic effects of Torin 1 on osteoarthritis by activating autophagy
por: Cheng, Ni-Tao, et al.
Publicado: (2016)

Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis
por: Sadowski, Samira M., et al.
Publicado: (2015)

While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts
por: Leontieva, Olga V., et al.
Publicado: (2017)

Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes
por: Xu, Song, et al.
Publicado: (2017)

Intra-articular injection of Torin 1 reduces degeneration of articular cartilage in a rabbit osteoarthritis model
por: Cheng, N-T., et al.
Publicado: (2016)

Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells
por: Atkin, Jane, et al.
Publicado: (2014)

Lifespan extension without fertility reduction following dietary addition of the autophagy activator Torin1 in Drosophila melanogaster
por: Mason, Janet S., et al.
Publicado: (2018)

Anti-inflammatory effects of Torin2 on lipopolysaccharide-treated RAW264.7 murine macrophages and potential mechanisms
por: Wei, Shanshan, et al.
Publicado: (2022)

Differential Role of Rapamycin and Torin/KU63794 in Inflammatory Response of 264.7 RAW Macrophages Stimulated by CA-MRSA
por: Shappley, Rebekah K. H., et al.
Publicado: (2014)

The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
por: Xiong, Zuquan, et al.
Publicado: (2017)

Effect of mesoporous silica nanoparticles co-loading with 17-AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2
por: Wang, Congcong, et al.
Publicado: (2020)

The therapeutic value of XL388 in human glioma cells
por: Zhong, Shan, et al.
Publicado: (2020)

A cell-based chemical-genetic screen for amino acid stress response inhibitors reveals torins reverse stress kinase GCN2 signaling
por: Brüggenthies, Johanna B., et al.
Publicado: (2022)

Torin1 restores proliferation rate in Charcot-Marie-Tooth disease type 2A cells harbouring MFN2 (mitofusin 2) mutation
por: Zanfardino, Paola, et al.
Publicado: (2022)

The Role of Green Tea Catechin Epigallocatechin Gallate (EGCG) and Mammalian Target of Rapamycin (mTOR) Inhibitor PP242 (Torkinib) in the Treatment of Spinal Cord Injury
por: Machova Urdzikova, Lucia, et al.
Publicado: (2023)

Smurf1 silencing restores PTEN expression that ameliorates progression of human glioblastoma and sensitizes tumor cells to mTORC1/C2 inhibitor Torin1
por: Xia, Qin, et al.
Publicado: (2021)

Torin 1 alleviates impairment of TFEB-mediated lysosomal biogenesis and autophagy in TGFBI (p.G623_H626del)-linked Thiel-Behnke corneal dystrophy
por: Wang, Liyuan, et al.
Publicado: (2021)

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
por: Blaser, Benjamin, et al.
Publicado: (2012)

Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition
por: Park, Dohyun, et al.
Publicado: (2016)

The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth
por: Soliman, Ghada A, et al.
Publicado: (2020)

Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics
por: Parate, Shraddha, et al.
Publicado: (2021)

Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
por: Jhanwar-Uniyal, Meena, et al.
Publicado: (2015)

The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models
por: Zhu, Yun-Rong, et al.
Publicado: (2016)

MBRS-18. TUMOR SUPPRESSOR p53 DEFINES THE THERAPEUTIC RESPONSES IN TREATMENT OF MEDULLOBLASTOMA
por: Mohan, Avinash L, et al.
Publicado: (2020)

CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
por: Badawi, Mohamed, et al.
Publicado: (2018)

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors
por: Ducker, Gregory S., et al.
Publicado: (2013)

Stem Cell Therapy and Curcumin Synergistically Enhance Recovery from Spinal Cord Injury
por: Ormond, D. Ryan, et al.
Publicado: (2014)

ATP-competitive mTOR kinase inhibitors delay plant growth by triggering early differentiation of meristematic cells but no developmental patterning change
por: Montané, Marie-Hélène, et al.
Publicado: (2013)

Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2(+/−) Mice
por: Jones, Ashley T., et al.
Publicado: (2019)

Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
por: Zhao, Hang, et al.
Publicado: (2019)

Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL
por: Shang, Yan Chen, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_i0tv081pf67a4nu824jhvjq7kc